ABITEC is a global leader in the development and manufacture of specialty lipids and surfactants. Through our world-class technical, scientific, regulatory and manufacturing expertise, we deliver the highest quality solutions in solubilisation, emulsification, and lubrication. Our mission is to develop and manufacture functional lipids to meet and exceed the application demands of the Pharmaceutical, Nutritional, and Specialty Chemical industries.
ABITEC’s lubricating dry binder for direct compression tableting STEROTEX® NF (Hydrogenated Vegetable Oil Type I), functions both as a boundary lubricant and as a dry binder. The oleaginous nature of Sterotex NF provides boundary lubrication to direct-compression tableting blends reducing ejection force. Sterotex NF also plastically deforms at relatively low compression pressures providing increased tablet hardness and reduced tablet friability making it an ideal dry binder for direct compression tableting operations.
PRIMARY ADVANTAGES:
• Freely flowing
• Plastically deforming at low compression pressures
• Provides boundary lubrication and reduces ejection force
• Economical compared to other dry binders
• Reduced effect on disintegration times compared with magnesium stearate
Additionally, ABITEC develops and manufactures a wide range of lipid-based excipients to enhance the bioavailability of poorly water-soluble and poorly permeable Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry. Applicable high-quality,monograph compliant lipid excipients for drug delivery applications are manufactured in ISO certified facilities in accordance with cGMP and applicable IPEC (International Pharmaceutical Excipient Council) guidelines.
ABITEC’s functional excipients can be incorporated into a broad range of pharmaceutical formulations and dosage forms including; soft-gelatin capsules, tablets, parenteral, topical, transdermal, ophthalmic and suppository bases. Please visit us at CPHI Stand 102D82 and/or AAPS Booth 1720 to learn more!
Company name: ABITEC Corporation
Website: www.abiteccorp.com E-mail: acoulter@abiteccorp.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.